THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB VS. ENTRECTINIB FOR TREATMENT OF METASTATIC FUSION-POSITIVE CANCERS IN CHILDREN AND YOUNG ADULTS

被引：0
|
作者：
Suh, K. [1 ]
Kang, A. [2 ]
Singh, R. [3 ]
Williamson, T. [3 ]
Sullivan, S. [4 ]
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
[2] Curta Inc, Seattle, WA USA
[3] Bayer US LLC, Whippany, NJ USA
[4] Univ Washington, Seattle, WA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO147
引用
收藏
页码：S44 / S45
页数：2
相关论文
共 50 条
  • [1] THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB VS. IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF METASTATIC NTRKGENE FUSION-POSITIVE CANCERS
    Suh, K.
    Kang, A.
    Ko, G.
    Williamson, T.
    Liao, N.
    Sullivan, S.
    VALUE IN HEALTH, 2023, 26 (06) : S55 - S55
  • [2] THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB VS. LENVATINIB OR SORAFENIB FOR TREATMENT OF NTRK FUSION-POSITIVE METASTATIC THYROID CANCER
    Carlson, J.
    Suh, K.
    Xia, F.
    Williamson, T.
    Sullivan, S.
    VALUE IN HEALTH, 2021, 24 : S20 - S20
  • [3] The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer
    Roth, Joshua A.
    Carlson, Josh J.
    Xia, Fang
    Williamson, Todd
    Sullivan, Sean D.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (08): : 981 - 986
  • [4] The Potential Long-Term Comparative Effectiveness of Larotrectinib vs. Entrectinib for Second-Line Treatment of NTRK Fusion-Positive Metastatic Non-Small Cell Lung Cancer
    Roth, Joshua A.
    Carlson, Josh J.
    Williamson, Todd
    Sullivan, Sean D.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [5] A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER"
    Ogale, Sarika
    Zerbini, Clarissa Emy Higuchi
    Antoniou, Miranta
    Freund, Romain
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (12): : 1616 - 1617
  • [6] A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER" RESPOND
    Roth, Joshua A.
    Carlson, Josh J.
    Xia, Fang
    Williamson, Todd
    Sullivan, Sean D.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (12): : 1617 - 1618
  • [7] The potential long-term comparative effectiveness of larotrectinib versus entrectinib for treatment of metastatic TRK fusion colorectal cancer
    Suh, Kangho
    Carlson, Josh John
    Xia, Fang
    Williamson, Todd E.
    Sullivan, Sean D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers
    Suh, Kangho
    Carlson, Josh J.
    Xia, Fang
    Williamson, Todd
    Sullivan, Sean D.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (14) : 1011 - 1019
  • [9] Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
    Drilon, A.
    Laetsch, T. W.
    Kummar, S.
    DuBois, S. G.
    Lassen, U. N.
    Demetri, G. D.
    Nathenson, M.
    Doebele, R. C.
    Farago, A. F.
    Pappo, A. S.
    Turpin, B.
    Dowlati, A.
    Brose, M. S.
    Mascarenhas, L.
    Federman, N.
    Berlin, J.
    El-Deiry, W. S.
    Baik, C.
    Deeken, J.
    Boni, V.
    Nagasubramanian, R.
    Taylor, M.
    Rudzinski, E. R.
    Meric-Bernstam, F.
    Sohal, D. P. S.
    Ma, P. C.
    Raez, L. E.
    Hechtman, J. F.
    Benayed, R.
    Ladanyi, M.
    Tuch, B. B.
    Ebata, K.
    Cruickshank, S.
    Ku, N. C.
    Cox, M. C.
    Hawkins, D. S.
    Hong, D. S.
    Hyman, D. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (08): : 731 - 739
  • [10] The potential long-term comparative effectiveness of larotrectinib versus regorafenib or trifluridine/tipiracil for treatment of metastatic TRK fusion colorectal cancer
    Suh, Kangho
    Carlson, Josh John
    Xia, Fang
    Williamson, Todd E.
    Sullivan, Sean D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345